 |
Tranzyme Pharma to Present at Upcoming Investor Conferences
Feb 21, 2012
|
10.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Vipin K. Garg, Ph.D., President and CEO, and Richard I. Eisenstadt, Vice President and CFO, will present at the following upcoming investor conferences:
Citi 2012 Global Health Care Conference taking place at The Waldorf Astoria, ...
|
|
Tranzyme Pharma to Report Fourth Quarter and Year-End 2011 Financial Results
Feb 14, 2012
|
10.9 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Wednesday, February 29, 2012 at 8:30 am ET to discuss fourth quarter and year-end 2011 financial results. The Company will report fourth quarter and year-end 2011 financial results after the close of ...
|
|
Tranzyme Pharma to Present at BIO CEO & Investor Conference
Feb 7, 2012
|
10.2 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will present at the BIO CEO & Investor Conference taking place at the Waldorf Astoria in New York, NY February 13-14, 2012. Tranzyme's presentation is scheduled for Monday, February 13th at 4:00...
|
|
Tranzyme Pharma Secures Additional $9.3 Million Debt Financing
Feb 1, 2012
|
16.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that it received an additional net $9.3 million in term loan proceeds through an amendment and restatement of its existing debt financing facility with Oxford Finance LLC and Horizon Technology Finance Corporation (Nasdaq:HRZN).
"We expe...
|
|
Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin
Dec 7, 2011
|
9.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 007, the first of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing partial bowel resection. There are an estima...
|
|
Tranzyme Pharma to Present at Piper Jaffray 23rd Annual Healthcare Conference
Nov 22, 2011
|
6.1 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin Garg, President and CEO, will present at the Piper Jaffray 23rd Annual Healthcare Conference taking place in New York on November 29 - 30, 2011. Tranzyme's presentation is scheduled for Tuesday, November 29 at 3:30 pm ET.
A ...
|
|
Tranzyme Pharma Announces Third Quarter 2011 Financial Results
Nov 10, 2011
|
19.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital‑based) and chronic gastrointestinal (GI) motility disorders today an...
|
|
Tranzyme Pharma Announces the Extension of Its Chemistry-Based Drug Discovery Collaboration With Bristol-Myers Squibb
Nov 8, 2011
|
9.7 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced the extension of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.
The coll...
|
|
Tranzyme Pharma to Report Third Quarter 2011 Financial Results
Nov 1, 2011
|
7.1 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will host a conference call on Friday, November 11, 2011 at 8:30 A.M. ET to discuss third quarter 2011 financial results. The Company will report third quarter 2011 financial results after the close of the market on Thursday, Novemb...
|
|
Tranzyme Pharma Ranked Number 54 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500(TM)
Oct 20, 2011
|
8.0 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced it ranked No. 54 on Deloitte's Technology Fast 500™, ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Tranzyme Pharma grew 2,239% percent during t...
|
|
Tranzyme Pharma to Present at the 10th Annual Bio Investor Forum
Oct 19, 2011
|
6.3 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin Garg, President and CEO, will present at the 10th Annual Bio Investor Forum taking place in San Francisco October 25 - 26, 2011. Tranzyme's presentation is scheduled for Tuesday, October 25 at 2:00 PM PT, 5:00 PM ET.
A live ...
|
|
Tranzyme Pharma Names Former Gilead Executive Franck Rousseau, M.D. Chief Medical Officer
Oct 18, 2011
|
9.7 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced the appointment of Franck Rousseau, M.D. to the newly created position of Chief Medical Officer. Dr. Rousseau will oversee the development of Tranzyme's clinical and preclinical portfolio including its most advanced drug candidates, ulimore...
|
|
Tranzyme Pharma Initiates Dosing in Phase 2b Trial of TZP-102 in Diabetic Patients With Gastroparesis
Oct 5, 2011
|
10.5 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Oct. 5, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it has dosed its first patient in a Phase 2b, 12-week trial of its first-in-class, oral, gastrointestinal (GI) motility drug candidate, TZP-102. The trial will be conducted in patients suffering from diabetic gastroparesis, a chronic, ...
|
|
Tranzyme Pharma Appoints George Abercrombie to Its Board of Directors
Sep 20, 2011
|
9.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced the appointment of George B. Abercrombie, R.Ph., M.B.A. to its Board of Directors and to serve on its Nominating and Corporate Governance Committee.
Mr. Abercrombie brings more than 30 years of pharmaceutical experience to Tranzyme Ph...
|
|
Tranzyme Pharma Announces Presentation of Additional Data for Its Oral Drug Candidate, TZP-102, at Annual Neurodiab Meeting in Porto, Portugal
Sep 12, 2011
|
10.4 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Niels Ejskjaer, M.D., Ph.D., Department of Endocrinology M, Aarhus University Hospital, Denmark, presented additional data from Tranzyme's Phase 2, 28-day study of its oral ghrelin agonist, TZP-102, supporting its potential role in t...
|
|
Tranzyme Pharma to Present at Upcoming Investor Conferences
Sep 7, 2011
|
7.3 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq: TZYM), today announced that Vipin Garg, President and CEO and Richard Eisenstadt, CFO will present at the following investor conferences in September:
Stifel Nicolaus Healthcare Conference 2011 taking place in Boston September 7-9. Tranzyme's presentation ...
|
|
Tranzyme Pharma Announces Management Change
Aug 25, 2011
|
9.4 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that Gordana Kosutic, M.D. has resigned as Vice President, Clinical and Regulatory Affairs, to pursue another opportunity. The Company has initiated a formal search for a Chief Medical Officer and has named M. Scott Harris, M.D., a consulta...
|
|
Tranzyme Pharma Announces Second Quarter 2011 Financial Results
Aug 11, 2011
|
17.6 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital‑based) and chronic gastrointestinal (GI) motility disorders toda...
|
|
David Moore Joins Tranzyme Pharma as Vice President, Commercial Operations
Aug 9, 2011
|
8.4 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that David Moore has joined the Company as Vice President, Commercial Operations, a newly created management position. In this role, Mr. Moore will be responsible for market development-related activities for Tranzyme's advanced drug candid...
|
|
Tranzyme Pharma to Report Second Quarter 2011 Financial Results
Aug 2, 2011
|
7.8 KB |
|
| |
RESEARCH TRIANGLE PARK, N.C., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that it will report second quarter 2011 financial results after the close of the market on Thursday, August 11, 2011. In connection with this announcement, the Company will host a conference call on Friday, August 12, 2011 at 8:30 A.M. ET t...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
